On May 19, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, reported that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021 (Press release, Castle Biosciences, MAY 19, 2021, View Source [SID1234580295]). Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, will provide a pre-recorded investor presentation and will be available for virtual one-on-one investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Meetings may be requested exclusively through Oppenheimer. The pre-recorded company presentation will be available via the conference site on May 26, 2021, and on the Castle Biosciences website at View Source from May 26 – June 16, 2021.